President, Co-Founder, CEO

Dr. Ezekowitz currently serves as President and CEO of Abide Therapeutics, a company he co-founded in 2011 with Professors Dale Boger and Ben Cravatt from the Scripps Research Institute. Prior to creating Abide, Dr. Ezekowitz was Senior Vice President and Franchise Head, Bone, Respiratory, Immunology, Respiratory, Bone and Muscle, Dermatology and Urology at Merck Research Laboratories, where he was responsible for the drug discovery and development process from target identification through proof of concept. He worked closely with his commercial General Manager to develop the life cycle strategy for approved drugs in those areas. He co-chaired the Joint Venture with Jansen to oversee the development of Remicade and Simponi in the EU.

Prior to Merck, Dr. Ezekowitz was the Charles Wilder Professor of Pediatrics at the Harvard Medical School and served as the Chief of Pediatric Services at the MassGeneral Hospital for Children and the Partners Healthcare System. He has served on multiple boards and committees, including the chair position of the Executive Committee on Research at Massachusetts General Hospital, the Board of Directors of the Partners Healthcare system and the MassGeneral Physicians Organization. He has also served on the Boards of Anika Therapeutics and Natimmune, a biotech company that he founded. He currently serves on the Board of Directors of Oxagen and Abide Therapeutics.

He served on many committees at the Harvard Medical School and chaired the committee that led to the establishment of the Academy at HMS and served as a Scholar and Founding Member. He is a member of the American Society of Clinical Investigation and a Fellow of AAAS. He has also been a part of multiple Subcommittees for the NIH. In 2008, he was honored with the establishment of the R. Alan Ezekowitz Professorship in Pediatrics at the Harvard Medical School.

He also directed the Laboratory of Developmental Immunology. He is a pioneer in the field of innate immunity and has over 150 publications. His group played a major role in defining the structure function of pattern recognition molecules like the mannose binding lectin and the macrophage mannose receptor. He was the Principal Investigator of an NIH Program Grant that included Jules Hoffmann (Nobel Laurette 2011 for the discovery of Toll receptors). His group’s contribution was the description of primordial phagocytic receptors. The work was published in Nature, Cell and Science. Furthermore, his work on phagocyte biology translated the effects of interferon gamma in vitro to create an FDA approved treatment for patients with Chronic Granulomatous Disease, a rare phagocytic disorder in humans.

Dr. Ezekowitz received his medical training at the University of Cape Town in South Africa and was awarded a Doctor of Philosophy degree from Oxford University, where he also completed a postdoctoral fellowship. At Children’s Hospital in Boston, he completed a second postdoctoral fellowship in the Division of Hematology and Oncology and his clinical training in pediatrics.


Richard and Alice Cramer Professor of Chemistry at The Scripps Research Institute

Dale Boger received his B.Sc. in chemistry from the University of Kansas, Lawrence, Kansas (1975, with highest distinction and honors in chemistry) and his Ph.D. in chemistry from Harvard University (1980) under the direction of E. J. Corey. He returned to the University of Kansas as a member of the faculty in the Department of Medicinal Chemistry (1979-1985), moved to the Department of Chemistry at Purdue University (1985-1991), and joined the faculty in the newly created Department of Chemistry at The Scripps Research Institute (1991-present) as the Richard and Alice Cramer Professor of Chemistry. Professor Boger is internationally recognized for his work in organic synthesis, medicinal chemistry, heterocyclic chemistry, natural products total synthesis and biological evaluation, synthetic methodology development, and combinatorial chemistry and has made seminal contributions to the understanding of the interaction of biologically active molecules with their targets (e.g., DNA-drug interactions of naturally occurring antitumor drugs, glycopeptide antibiotic binding with bacterial cell wall precursors). He was a founder of CombiChem, a long term consultant to several major pharmaceutical companies (Dupont/Dupont-Merck, J&J), a Scientific Advisory Board member for many biotech firms (Rib-X, Conforma, Neurocrine, 3D Pharmecueticals), has served as an advisor to more than 50 PhD and 150 postdoctoral students, and is the coauthor of more than 500 publications and 2 books. He was the founder Editor and continues to serve as the Editor-in-Chief for Bioorganic and Medicinal Chemistry Letters.


Vice President, Product & Business Development at Maxygen, Inc. Kauffman Fellow

Keith Lenden is currently the Vice President of Product and Business Development at Maxygen where he’s building a public-private partnership with the US Government to develop medical countermeasures against radiological or nuclear attack. As an entrepreneur, Keith is a Co-Founder of two biotechnology companies – Abide Therapeutics and Receptos – and is a Kauffman Fellow. Previously as head of business development at Genteric and Acologix, Keith led development teams on both small and large molecule programs and completed multiple partnership transactions. Keith started his career in biotechnology at LEK Consulting working on product and corporate strategy, marketing, business development and M&A project teams. Keith is an active member and on the faculty of the Licensing Executives Society and has worked with both the Business Development Committee and BioDefense Working Group of the Biotechnology Industry Organization. He is also a Certified Licensing Professional.Keith earned an MBA from UC Berkeley’s Haas School of Business and was a Price Institute for Entrepreneurial Studies Venture Capital Fellow. Keith has since taught an MBA level course at Haas on Corporate Development and M&A. Keith also studied engineering at Dartmouth College’s Thayer School. Keith is a Founding Director of the Kaiser Education Foundation, a not-for-profit organization that makes micro-scholarships to Dartmouth undergraduates. Keith is married with two daughters and enjoys live music, hiking, running and playing golf.



Todd Jones, Ph.D., has over twenty years of experience in drug discovery and development in both pharmaceutical and biotechnology companies. He is a co-founder for Abide Therapeutics.

Prior to Abide, Todd served as Vice President of Chemistry & Enabling Technologies at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) where he had responsibility for establishing, building and guiding Medicinal Chemistry, Biology Enabling Research Technologies (Compound Logistics, Developability, Drug Metabolism & Pharmacokinetics, Genomics and High Throughput Screening), Scale-up Chemistry, Analytical Chemistry, and Computational Chemistry. During Todd’s leadership tenure, the J&JPRD La Jolla site generated over thirty new molecular entities that were accepted into development with more than fifteen advancing into human clinical trials.

Prior to J&JPRD, Todd held positions of increasing responsibility at Ontogen Corporation, an automated high-throughput chemical-synthesis drug discovery company, and Ligand Pharmaceuticals, a cutting-edge drug discovery biotechnology company, in San Diego. Todd began his pharmaceutical career at Merck Research Laboratories in Rahway, NJ, where he gained experience in process and medicinal chemistry. Todd has been involved in projects spanning anti-parasitic, inflammatory, metabolic, neuroscience, oncology, pain, and reproductive medicine therapeutic areas. He is an inventor on more than ninety issued United States patents and a co-author on over sixty peer-reviewed scientific publications.

Todd earned his B.S. in chemistry from the Colorado School of Mines in Golden, CO, followed by a Ph.D. in chemistry from the University of Illinois at Urbana-Champaign, IL, in Professor Scott Denmark’s laboratories. He was awarded a National Institutes of Health postdoctoral fellowship at Harvard University in Cambridge, MA, under the direction of Professor David Evans.


Professor and Chair of the Department of Chemical Physiology
at The Scripps Research Institute

Dr. Cravatt’s research group is interested in understanding the roles that enzymes play in physiological and pathological processes, especially as pertains to the nervous system and cancer. To address this challenge, they develop and apply an array of biochemical, chemical, and genetic technologies.

The Cravatt group has obtained fundamental insights into the chemical, biochemical, and physiological workings of several important mammalian serine hydrolases, including enzymes involved in the neurobiology of pain and in proteases associated with tumor progression.Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then trained with Drs. Dale Boger and Richard Lerner and received a Ph.D. in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997 as a member of the Skaggs Institute for Chemical Biology and the departments of Cell Biology and Chemistry. His honors include a Searle Scholar Award (1998-2001), the Eli Lilly Award in Biological Chemistry (2004), a Cope Scholar Award (2005), the Irving Sigal Young Investigator Award (2007) and the Tetrahedron Young Investigator Award in Bioorganic and Medicinal Chemistry (2008).


Managing Partner. Princeton, NJ Office

John Clarke has a 30 year record of early-stage venture capital investment success. John co-founded Cardinal Partners in 1997 and currently serves as a Managing Partner of the firm. John leads Cardinal’s life sciences investment efforts and has had an extraordinary record of success.

John led the firm’s investment in Cubist Pharmaceuticals (Nasdaq:CBST – 3x return/6 mos.), Momenta Pharmaceuticals (Nasdaq:MNTA – 8x return/4 yrs.), Alnylam Pharmaceuticals (Nasdaq:ALNY – 4x return/4 yrs.) and Sirtris Pharmaceuticals (Nasdaq:SIRT – acquired by GSK – 6x return/4 yrs.). John also spearheaded Cardinal’s investment in and served as a director for: TechRx Corporation (acquired by NDCHealth/4x return) and Visicu (Nasdaq:EICU – acquired by Phillips Electronics/11x return). John currently serves on the Board of Directors for Cardinal portfolio companies Abide Therapeutics, aTyr Pharma, Rib-X Pharmaceuticals (observer) and Verastem, as well as Alnylam Pharmaceuticals and Momenta Pharmaceuticals.John entered the venture industry in 1982 with DSV Partners, a pioneer venture capital fund formed in 1968. John led DSV’s health care and life sciences efforts, and was a co-founder and served as interim CEO of numerous successful companies including Alkermes (Nasdaq:ALKS), Arris Pharmaceuticals (Nasdaq:ARRS), DNX (Nasdaq:DNXX) and Cubist Pharmaceuticals (Nasdaq:CBST). As managing partner at DSV in that firm’s latter years, John led the firm’s evolution into Cardinal Partners.

John has served on the National Venture Capital Association’s Board of Directors where he was Chairman of its Regulatory Committee and Membership Committee. John was a founding director of the Greater Philadelphia Venture Group as well as its past President and Chairman. John is a past member of the Board of Directors of the Greater Philadelphia Chamber of Commerce and the Board of the Philadelphia Industrial Development Corporation Penn Venture Group. He has served as a member of the University of Pennsylvania Advisory Panel on Technology Transfer. John is also a Trustee of Hands Together, a non-profit organization that provides health care and education support to the needy in Haiti. Prior to his venture capital career, John worked for the General Electric Company in various sales and marketing positions.

John received his B.A. in Economics and Biology from Harvard University and his M.B.A. from the Wharton School at the University of Pennsylvania.


Ernest and Jean Hahn Professor
at The Skaggs Institute for Chemical Biology
at The Scripps Research Institute

Dr. Schimmel earned his Ph.D. in biology at MIT in 1966 and was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT.

Schimmel is author or co-author of more than 450 scientific papers and of a widely used three volume textbook on biophysical chemistry. Schimmel has been honored as an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences, the American Philosophical Society, and the Institute of Medicine. Having a longstanding interest in the applications of basic biomedical research to human health, Schimmel holds numerous patents and is a cofounder or founding director of several biotechnology companies, of which six have become publicly traded.